Not Only Spray-Drying – Particle Engineering in Dry Powder Inhaler (DPI) Formulations
Prof. Dr. Regina Scherließ, University of Kiel
Not Only Spray-Drying – Particle Engineering in Dry Powder Inhaler (DPI) Formulations
Prof. Dr. Regina Scherließ, University of Kiel
Connecting Ps of dry powder inhalation (DPI) development: Particles, properties, processing, and performance
Dr. Amrit Paudel, Technical University Graz
Controlling Shape and Structure of Supraparticles by Tuning Colloidal Interactions
Dr. Michael Kappl, Max-Planck-Institute
How to Discriminate Dissolution Profiles of Engineered Powders
Dr. Francesca Buttini, University of Parma
Formulation and Production of Carrier-Free Powders for Dry Powder Inhalers (DPIs)
Prof. Dr. Anne Marie Healy, Trinity College Dublin
Advanced Lipid Excipients (Polyglyceryl-Ester) for Pulmonal Drug Delivery: Overcoming the Challenges of Conventional Formulations
Priv-Doz. Dr. Sharareh Salar-Behzadi, RCPE
Particle Engineering by Crystallization
Dr. Peter Neugebauer, Technical University Graz
Particle Engineering and Drug Delivery by Inhalation: Barriers and Opportunities to get to the market – An Industry Perspective
Dr. Alessandro Cavecchi, Chiesi Farmaceutici
Linking Particle Properties to Their Predicted In-Vivo Performance: An In-Vitro-In-Silico Case Study Using Different Lactose Grades
Dr. Joana Pinto, RCPE
My research interests include disperse systems and nanoparticles, stabilisation of biomolecules and particle engineering in spray drying and formulations for mucosal vaccination with a focus on respiratory (nasal and pulmonary) dry powder delivery. My work comprises formulation development and optimisation, functional characterisation as well as basic research exploring underlying principles in formulation and performance. Recent projects work on novel non-spherical dry powder carriers, softpellets and drug nanocrystals for high dose application of powders to the lung, mucosal vaccination via the respiratory tract, nose-to-brain delivery, the in vitro assessment of nasal excipients, the exploration of surface energy in powders for inhalation and the development of nanoparticulate drug carrier systems.
Since 2002 he is group leader at the MPI-P, working in the fields of surface forces, wetting and characterization of mechanical properties on the micro- and nanoscale. In addition he is heading the Focused Ion Beam Service Lab, providing service for nanostructuring, cross-sectioning of samples, preparation of TEM lamella, and 3D tomography.
His research is focused on surface forces and mechanics on nano- and microscale and wetting.
Professor Healy has published extensively, with over 110 international peer reviewed publications. She has graduated 21 PhD students, mentored 26 postdoctoral researchers, and has been awarded €10 million in competitive grant income.
Her research interests include pharmaceutical material science, preformulation and formulation of pharmaceuticals, amorphous solids, co-crystals, formulating poorly soluble drugs, pharmaceutical processing and pulmonary drug delivery.
Anne Marie is a Co-Principal Investigator of the SSPC - the Science Foundation Ireland Research Centre for Pharmaceuticals (www.sspc.ie) and is one of the Co-Directors of the EPSRC-SFI Centre for Doctoral Training in Transformative Pharmaceutical Technologies (https://www.transpharmtech-dtc.ac.uk/).
He received his Ph.D. in the area of particle technology in 1995 from the Graz University of Technology in 1995. He was then a post doctoral fellow at the University of Houston with Prof. Dan Luss. In 1998 Prof. Khinast joined Rutgers University (New Jersey, USA) as an assistant professor, where he was granted early tenure in 2003. During his period at Rutgers University Prof. Khinast received several important awards, including the Bristol-Myers Squibb Young Faculty Development Award (1999), the DuPont Young Professor Award (2000), the North American Mixing Forum Award (2000) and finally in 2001 the prestigious NSF CAREER Award. In 2005 Prof. Khinast was selected as a Marie Curie Chair of the EU, and in 2006 he was offered a professorship at the Graz University of Technology. Prof. Khinast has received significant funding for his work in process simulation, pharmaceutical process engineering and particle technology in the order of more than 80 million Euros from various sources.
He also has worked with a large number of pharmaceutical and equipment companies and serves an advisor for the implementation of novel technology. He has supervised more than 40 Ph.D. students and PostDocs and his publication record encompasses over 300 peer-reviewed publications and 8 book chapters. He also holds 11 patents in the area of pharmaceutical manufacturing.
I co-authored 15 patent families.
Throughout my career, I licensed successfully technologies and products including nanotechnologies for poorly soluble drugs. As member of the leadership team, I was jointly responsible for four financing rounds. In addition, I served 4 years as board member at Novaliq.
In 2003, I was founder of APISPHARMA AG, a consulting firm, covering the whole value chain from idea to market, including licensing, IP and business development in the biomedical industry for innovative dosage forms, mainly active in the start-up environment.
From 2003 until 2016 I worked in the start-up environment in a variety of func-tions.
In 2013, I became CSO at Novaliq after serving 4 years as Board Member and Head of Business Development. In this function I developed the core of Novaliq IP, 10 patent families, developed a novel drug delivery technology for eye drops from concept to market launch (EvoTears
As from 2016, I started at Lonza as Senior Advisor and subsequently becoming Head Application Development Excipients in 2017, responsible for the devel-opment of an improved generation of pharmaceutical excipients, leading to 3 patent families (not published yet).
I have worked within international teams and in different cultural environments for companies throughout Europe, including Germany, Switzerland, Denmark, and Sweden. This led to an extensive network both, in industry and academia.
I am an open minded, curious and innovative personality with a high grade of dedi-cation and result orientation combined with business sense and strength for identi-fying out of the box solutions.
Combining her background in pharmaceutical technology, regulatory aspects and device construction, she is leading and executing research programs aimed to deliver medicinal products that take into consideration the patient, industrial and regulatory requirements. As a result of her research achievement she obtained in 2017 the DDL Emerging Scientist Awards from the UK Aerosol Society.
Francesca Buttini is a founder of PlumeStars, an innovative SME, dedicated to development of orphan drug products to treat lung and systemic disease by inhalation therapy.
Tickets are refundable up to 30 days before the event starts
However, particle engineering has moved beyond simple particle size control. New technologies and innovative approaches have led to a revolution in the field. This workshop is dedicated to these developments. Researchers will present their most recent innovations, including novel excipients for pharmaceutical applications, particle characterizations, and simulative approaches. Innovations that allow us to break new grounds in drug delivery, such as inhalation, and maximize the therapeutic potential of a diverse range of particles.
For the first time, we will be hosting a pitch competition for emerging scientists currently enrolled in a Ph.D. Degree Programme. Show us that your work will change how we design and engineer particles in the future. Blow us away with a presentation that is just on point and leaves us demanding more, and walk away with the grand prize after being judged by a jury of your peers.
All you need to do is simply submit a one-page abstract describing your work using the official template. We will evaluate your work and select 7 lucky contestants for the live session in Graz.
Evaluation Committee:
Prof. Dr. Johannes Khinast – CEO & Scientific Director RCPE
Prof. Dr. Eva Roblegg – University of Graz
Assoc. Prof. Dr. Francesca Buttini – University of Parma
Dr. Sarah Neugebauer – Senior Scientist RCPE
The workshop is about connections. We connect theory and practice, researchers with industrial counterparts, and most importantly, problem solvers with solution seekers. This workshop is part of the international Galenus Workshop Series and receives additional funding by RCPE.
The safety and protection of participants is of the utmost importance. We will follow health and safety measures issued at the time of the events by federal and local authorities. Before the workshop you will receive additional information on enforced risk mitigation measures.
Limited Event Capacity
Attendance in all events areas will be limited as per venue requirements.
Personal Protective Equipment
Face coverings will be provided for all attendees, and guests. Hand sanitizing products will be made available throughout the event space.
Entry into Austria and Pre-Travel Clearance
For information on possible entry regulations and needed verification, please refer to the official website of the Austrian government.
These measures will be adjusted based on changes to state and local requirement. For more information, refer to this overview on the coronavirus situtation in Austria.
We are pleased to answer any questions you may have about the workshop and we will respond to your requests immediately.
Dr. Sarah Neugebauer
Senior Scientist
T +43 316 873 30945
E sarah.neugebauer@rcpe.at
Constantin Schmidt, BA MA MA
Head of Marketing & PR
T +43 316 873 35915
E constantin.schmidt@rcpe.at